Apoptosis: A new pharmacodynamic endpoint

被引：37

作者：

Au, JLS

Panchal, N

Li, D

Gan, YB

机构：

[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

来源：

PHARMACEUTICAL RESEARCH | 1997年 / 14卷 / 12期

关键词：

apoptosis; programmed cell death; drug induced apoptosis; pharmacodynamic endpoint;

D O I：

10.1023/A:1012159208559

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

[No abstract available]

引用

页码：1659 / 1671

页数：13

共 197 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2]

Ahmad M, 1997, CANCER RES, V57, P615

[3]

Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1

[4]

BAFFY G, 1993, J BIOL CHEM, V268, P6511

[5]

BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487

[6] CELL-DEATH IN HEALTH AND DISEASE - THE BIOLOGY AND REGULATION OF APOPTOSIS [J].

BELLAMY, COC ;

MALCOMSON, RDG ;

HARRISON, DJ ;

WYLLIE, AH .

SEMINARS IN CANCER BIOLOGY, 1995, 6 (01) :3-16

[7]

BELLOMO G, 1992, CANCER RES, V52, P1342

[8]

BERTRAND R, 1991, CANCER RES, V51, P6280

[9]

Blagosklonny MV, 1997, CANCER RES, V57, P130

[10]

Blagosklonny MV, 1996, CANCER RES, V56, P1851

← 1 2 3 4 5 6 7 8 9 10 →